PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2017-09-01
|
Series: | Radiology and Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1515/raon-2017-0037 |
id |
doaj-9104b551aa43462e8b685d9eeb1a62eb |
---|---|
record_format |
Article |
spelling |
doaj-9104b551aa43462e8b685d9eeb1a62eb2021-09-05T14:00:10ZengSciendoRadiology and Oncology1581-32072017-09-0151335736210.1515/raon-2017-0037raon-2017-0037PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lungJanzic Urska0Kern Izidor1Janzic Andrej2Cavka Luka3Cufer Tanja4Department of Medical Oncology, University Clinic Golnik, Golnik, SloveniaDepartment of Pathology, University Clinic Golnik, Golnik, SloveniaUniversity of Ljubljana, Faculty of Pharmacy, Ljubljana, SloveniaDepartment of Medical Oncology, Institute of Oncology, Ljubljana, SloveniaDepartment of Medical Oncology, University Clinic Golnik, Golnik, SloveniaWith introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients.https://doi.org/10.1515/raon-2017-0037lung cancersquamous-cell lung canceradenocarcinomatumor cellsimmune cellspd-l1 expression |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Janzic Urska Kern Izidor Janzic Andrej Cavka Luka Cufer Tanja |
spellingShingle |
Janzic Urska Kern Izidor Janzic Andrej Cavka Luka Cufer Tanja PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung Radiology and Oncology lung cancer squamous-cell lung cancer adenocarcinoma tumor cells immune cells pd-l1 expression |
author_facet |
Janzic Urska Kern Izidor Janzic Andrej Cavka Luka Cufer Tanja |
author_sort |
Janzic Urska |
title |
PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung |
title_short |
PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung |
title_full |
PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung |
title_fullStr |
PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung |
title_full_unstemmed |
PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung |
title_sort |
pd-l1 expression in squamous-cell carcinoma and adenocarcinoma of the lung |
publisher |
Sciendo |
series |
Radiology and Oncology |
issn |
1581-3207 |
publishDate |
2017-09-01 |
description |
With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients. |
topic |
lung cancer squamous-cell lung cancer adenocarcinoma tumor cells immune cells pd-l1 expression |
url |
https://doi.org/10.1515/raon-2017-0037 |
work_keys_str_mv |
AT janzicurska pdl1expressioninsquamouscellcarcinomaandadenocarcinomaofthelung AT kernizidor pdl1expressioninsquamouscellcarcinomaandadenocarcinomaofthelung AT janzicandrej pdl1expressioninsquamouscellcarcinomaandadenocarcinomaofthelung AT cavkaluka pdl1expressioninsquamouscellcarcinomaandadenocarcinomaofthelung AT cufertanja pdl1expressioninsquamouscellcarcinomaandadenocarcinomaofthelung |
_version_ |
1717812364190941184 |